Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Author:

Ahn Inhye E.1,Farooqui Mohammed Z. H.1,Tian Xin2,Valdez Janet1,Sun Clare1,Soto Susan1,Lotter Jennifer1,Housel Stephanie13,Stetler-Stevenson Maryalice4,Yuan Constance M.4,Maric Irina5,Calvo Katherine R.5,Nierman Pia1,Hughes Thomas E.6,Saba Nakhle S.17,Marti Gerald E.1,Pittaluga Stefania4,Herman Sarah E. M.1,Niemann Carsten U.18,Pedersen Lone B.8,Geisler Christian H.8,Childs Richard1,Aue Georg1,Wiestner Adrian1

Affiliation:

1. Hematology Branch and

2. Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;

3. Leidos Biomedical Research, Inc., Bethesda, MD;

4. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute,

5. Department of Laboratory Medicine, Clinical Research Center, and

6. Department of Pharmacy, Clinical Research Center, National Institutes of Health, Bethesda, MD;

7. Section of Hematology and Medical Oncology, Department of Medicine, Tulane University, New Orleans, LA; and

8. Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Abstract

Key Points With 5-year median follow-up, continuous single-agent ibrutinib therapy was well tolerated with deepening of response. Previously untreated patients, even those with TP53 aberration, achieved durable responses.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 169 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3